Contineum Therapeutics (CTNM) Net Cash Flow (2023 - 2026)

Contineum Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at -$55.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 10620.87% year-over-year to -$55.4 million in Q1 2026; TTM through Mar 2026 was -$2.3 million, a 137.25% decrease from a year earlier, with the FY2025 full-year figure at $53.7 million, up 736.22% from the prior year.
• Net Cash Flow eased to -$55.4 million in Q1 2026 per CTNM's latest filing, from $33.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $61.0 million in Q2 2024 and bottomed at -$55.4 million in Q1 2026.
• The 4-year median for Net Cash Flow is $527000.0 (2025), against an average of $1.1 million.
• Across the five-year window, Net Cash Flow soared 274.0% in 2025 and plunged 10620.87% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$2.0 million in 2023, then plunged by 849.77% to -$18.9 million in 2024, then surged by 274.0% to $33.0 million in 2025, then sank by 268.17% to -$55.4 million in 2026.
• Per Business Quant, the three latest CTNM Net Cash Flow figures stand at -$55.4 million (Q1 2026), $33.0 million (Q4 2025), and $21.8 million (Q3 2025).